-
Something wrong with this record ?
Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators
J. Kozempel, O. Mokhodoeva, M. Vlk,
Language English Country Switzerland
Document type Journal Article, Review
NLK
Directory of Open Access Journals
from 1997
Free Medical Journals
from 1997
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 1997-01-01
Open Access Digital Library
from 1997-01-01
Medline Complete (EBSCOhost)
from 2009-03-01
Health & Medicine (ProQuest)
from 1997-01-01
- MeSH
- Actinium chemistry therapeutic use MeSH
- Alpha Particles therapeutic use MeSH
- Astatine chemistry therapeutic use MeSH
- Bismuth chemistry therapeutic use MeSH
- Chelating Agents chemistry pharmacokinetics MeSH
- Radiation Dosage MeSH
- Heterocyclic Compounds, 1-Ring chemistry pharmacokinetics MeSH
- Heterocyclic Compounds chemistry pharmacokinetics MeSH
- Small Molecule Libraries chemistry pharmacokinetics MeSH
- Humans MeSH
- Neoplasms pathology radiotherapy MeSH
- Drug Carriers administration & dosage chemistry MeSH
- Radiopharmaceuticals chemistry therapeutic use MeSH
- Radioisotopes chemistry therapeutic use MeSH
- Radium chemistry therapeutic use MeSH
- Dose-Response Relationship, Radiation MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like 211At, 223Ra, 225Ac/213Bi, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitting nuclides and their biomolecular targets as well as nanocarriers), general radiopharmaceutical issues, preclinical studies, and clinical trials including the possibilities of therapy prognosis and follow-up imaging. Special attention is given to the nuclear recoil effect and its impacts on the possible use of alpha emitters for cancer treatment, proper dose estimation, and labelling chemistry. The most recent and important achievements in the development of alpha emitters carrying vectors for preclinical and clinical use are highlighted along with an outlook for future developments.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033262
- 003
- CZ-PrNML
- 005
- 20181010124957.0
- 007
- ta
- 008
- 181008s2018 sz f 000 00|eng||
- 009
- AR
- 024 7_
- $a 10.3390/molecules23030581 $2 doi
- 035 __
- $a (PubMed)29510568
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kozempel, Ján $u Czech Technical University in Prague, Faculty of Nuclear Sciences and Physical Engineering, Prague CZ-11519, Czech Republic. jan.kozempel@fjfi.cvut.cz.
- 245 10
- $a Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators / $c J. Kozempel, O. Mokhodoeva, M. Vlk,
- 520 9_
- $a This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like 211At, 223Ra, 225Ac/213Bi, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitting nuclides and their biomolecular targets as well as nanocarriers), general radiopharmaceutical issues, preclinical studies, and clinical trials including the possibilities of therapy prognosis and follow-up imaging. Special attention is given to the nuclear recoil effect and its impacts on the possible use of alpha emitters for cancer treatment, proper dose estimation, and labelling chemistry. The most recent and important achievements in the development of alpha emitters carrying vectors for preclinical and clinical use are highlighted along with an outlook for future developments.
- 650 _2
- $a aktinium $x chemie $x terapeutické užití $7 D000186
- 650 _2
- $a alfa částice $x terapeutické užití $7 D000512
- 650 _2
- $a astat $x chemie $x terapeutické užití $7 D001246
- 650 _2
- $a bismut $x chemie $x terapeutické užití $7 D001729
- 650 _2
- $a chelátory $x chemie $x farmakokinetika $7 D002614
- 650 _2
- $a vztah dávky záření a odpovědi $7 D004307
- 650 _2
- $a nosiče léků $x aplikace a dávkování $x chemie $7 D004337
- 650 _2
- $a heterocyklické sloučeniny $x chemie $x farmakokinetika $7 D006571
- 650 _2
- $a heterocyklické sloučeniny monocyklické $x chemie $x farmakokinetika $7 D006573
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory $x patologie $x radioterapie $7 D009369
- 650 _2
- $a dávka záření $7 D011829
- 650 _2
- $a radionuklidy $x chemie $x terapeutické užití $7 D011868
- 650 _2
- $a radiofarmaka $x chemie $x terapeutické užití $7 D019275
- 650 _2
- $a radium $x chemie $x terapeutické užití $7 D011883
- 650 _2
- $a knihovny malých molekul $x chemie $x farmakokinetika $7 D054852
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Mokhodoeva, Olga $u Vernadsky Institute of Geochemistry and Analytical Chemistry, Moscow 119991, Russia. olga.mokhodoeva@mail.ru.
- 700 1_
- $a Vlk, Martin $u Czech Technical University in Prague, Faculty of Nuclear Sciences and Physical Engineering, Prague CZ-11519, Czech Republic. martin.vlk@fjfi.cvut.cz.
- 773 0_
- $w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 23, č. 3 (2018)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29510568 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181010125446 $b ABA008
- 999 __
- $a ok $b bmc $g 1340863 $s 1030256
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 23 $c 3 $e 20180305 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- LZP __
- $a Pubmed-20181008
